Figure 4.

SLC39A4 strengthens chemoresistance of ESCC cells in vitro. (A) SLC39A4-depleted TE-1 or TE-10 cells underwent increased apoptosis compared to the negative control. Data, mean ± SD, *P < 0.05, **P < 0.01. (B) Over-expression of SLC39A4 reduced cisplatin-induced apoptosis in TE-1 and TE-10 cells. Data, mean ± SD, *P < 0.05, **P < 0.01. (C) Until transfected with siNC or siSLC39A4 for 48 hours, ESCC cells were treated with cisplatin in different dosages for 24 hours. The results of cisplatin IC50 detection showed that depletion of SLC39A4 circumvented the resistance toward cisplatin in TE-1 and TE-10 cells. Bar, SD for quintuplicate wells. (D) The reduced IC₅₀ to cisplatin was observed in both TE-1 and TE-10 cells treated with TPEN (3μM). Bar, SD for quintuplicate wells. CDDP, cisplatin. IC50, the half maximal inhibitory concentration.